House Democrats ask pharma CEOs to explain insulin pricing

House Democrats Wednesday asked Eli Lilly and Co. (NYSE:LLY), Novo Nordisk A/S (CSE:NOVO B; NYSE:NVO) and Sanofi (NASDAQ:SNY; Euronext:SAN) to justify all insulin product price increases over the past decade and disclose any deals that may have inhibited generic

Read the full 399 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE